Icon

ZEPOSIA (nda209899)- (EQ 0.23MG BASE,EQ 0.46MG BASE,EQ 0.92MG BASE)

OZANIMOD HYDROCHLORIDE BRISTOL
EQ 0.23MG BASE,EQ 0.46MG BASE,EQ 0.92MG BASE
Yes No
2038-Sep-30 2025-Mar-25
None None
None No
ZEPOSIA is a sphingosine 1-phosphate receptor modulator indicated for the treatment of: • Relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. • Moderately to severely active ulcerative colitis (UC) in adults.
0 0 0
Total Other Developers 2
Drugs with Suitability No
EQ 0.23MG BASE ** ** - - -
EQ 0.46MG BASE ** ** - - -
EQ 0.92MG BASE ** ** - - -
NDA Sales Available Total Generic Sales Available
Yes 0
ANDA No Generic Co Manufacturer Name Operations Manufacturer Address Country

GenUs Advanced Search




Expired
to
Expired
to


Please contact contact@researchdelta.com to get more details.